Categories: HealthcareNews

Stryker declares an $0.88 per share quarterly dividend

Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter. 

“We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 per share,” said Kevin Lobo, Chair and Chief Executive Officer, Stryker.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries:
Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or jason.beach@stryker.com 

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com

Staff

Recent Posts

Gargle Launches “Straighten While You…”–A Hyper‑Local Clear Aligner Marketing Platform That Reaches Patients Where They Live Life

LEHI, Utah, Jan. 24, 2026 /PRNewswire/ -- Gargle, Inc., a premier dental marketing partner, officially…

3 hours ago

Ireland Acute Care EHR and Digital Health 2026 Report Released

Black Book Market Research announces an independent, decision grade companion report available gratis to global…

3 hours ago

University Medical Center Southern Nevada Becomes First Hospital in Nevada to Earn Magnet Recognition

Prestigious designation recognizes excellence in nursing, patient care, and clinical outcomesLAS VEGAS, Jan. 24, 2026…

6 hours ago

Direct Meds NAD+ Injections Consumer Report 2026: Comparing Supplement and Peptide Alternatives, Dosage, Benefits & Side Effects

A consumer-focused examination of NAD+ injections, NAD+ supplements, NAD+ peptides, NAD+ dosage protocols, documented NAD+…

6 hours ago

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today…

6 hours ago

Nexalin Technology Receives Nasdaq Listing Status Notification

HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company”…

6 hours ago